Novel Vitamin E Analogues with Enhanced Specificity for Malignant Cells

新型维生素 E 类似物对恶性细胞具有增强的特异性

• 批准号: DP0453372
• 负责人: Prof Jiri Neuzil
• 金额: $ 14.56万
• 依托单位: Griffith University
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2004
• 资助国家: 澳大利亚
• 起止时间: 2004-01-01 至 2007-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0453372
• 关键词: Novel; Vitamin; Analogues; Enhanced; Specificity

The aim of this project is to synthesise and characterise novel compounds based on vitamin E succinate that are capable of efficiently and selectively killing cancer cells. The new compounds will be tested for their ability to induce programmed cell death in cancer cells and the most active of them will be also tested for anti-cancer effect in a pre-clinical model. We believe that novel analogues based on vitamin E succinate can lead to the discovery of very effcient and selective anti-cancer drugs with no side-effects that may be used for patient treatment in the future. This makes our project of exceptional significance.

该项目的目的是合成和表征基于维生素E琥珀酸酯的新型化合物，这些化合物能够有效和选择性地杀死癌细胞。新化合物将被测试它们诱导癌细胞程序性细胞死亡的能力，其中最活跃的化合物也将在临床前模型中测试抗癌效果。我们相信，基于维生素E琥珀酸酯的新型类似物可以导致发现非常有效、选择性强、没有副作用的抗癌药物，这些药物可能在未来用于患者治疗。这使得我们的项目具有特殊的意义。